Access the full text.
Sign up today, get DeepDyve free for 14 days.
Haruka Sato, K. Sugimura, M. Miura, R. Konno, Katsuya Kozu, N. Yaoita, Toru Shimizu, S. Yamamoto, T. Aoki, S. Tatebe, K. Satoh, H. Shimokawa (2019)Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease.
The Tohoku journal of experimental medicine, 247 2
D. Montani, E. Lau, P. Dorfmüller, B. Girerd, X. Jaïs, L. Savale, F. Perros, E. Nossent, Gilles Garcia, F. Parent, E. Fadel, F. Soubrier, O. Sitbon, G. Simonneau, M. Humbert (2016)Pulmonary veno-occlusive disease
European Respiratory Journal, 47
A. Ogawa, S. Sakao, N. Tanabe, H. Matsubara, K. Tatsumi (2019)Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review.
Respiratory investigation, 57 2
A Ogawa (2019)183
Respir Investig, 57
BW Holcomb, JE Loyd, EW Ely, J Johnson, IM Robbins (2000)Pulmonary veno-occlusive disease: a case series and new observations
M. Humbert, G. Kovacs, M. Hoeper, R. Badagliacca, R. Berger, M. Brida, J. Carlsen, A. Coats, P. Escribano-Subías, P. Ferrari, D. Ferreira, H. Ghofrani, G. Giannakoulas, D. Kiely, E. Mayer, G. Meszaros, Blin Nagavci, K. Olsson, J. Pepke-Zaba, J. Quint, G. Rådegran, G. Simonneau, O. Sitbon, T. Tonia, M. Toshner, J. Vachiéry, A. Noordegraaf, M. Delcroix, S. Rosenkranz (2022)2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
European heart journal
N. Galiè, M. Humbert, J. Vachiéry, S. Gibbs, I. Lang, A. Torbicki, G. Simonneau, A. Peacock, A. Noordegraaf, M. Beghetti, A. Ghofrani, M. Sánchez, G. Hansmann, W. Klepetko, P. Lancellotti, M. Matucci, T. McDonagh, L. Pierard, P. Trindade, M. Zompatori, M. Hoeper (2015)2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
European Respiratory Journal, 46
Barry Jr., J. Loyd, E. Ely, Joyce Johnson, I. Robbins (2000)Clinical InvestigationsPULMONARY VASCULATUREPulmonary Veno-occlusive Disease: A Case Series and New Observations
N Galiè (2015)903
Eur Respir J, 46
MM Hoeper (2013)1128
D. Montani, B. Girerd, X. Jaïs, M. Levy, D. Amar, L. Savale, P. Dorfmüller, A. Seferian, E. Lau, M. Eyries, J. Pavec, F. Parent, D. Bonnet, F. Soubrier, E. Fadel, O. Sitbon, G. Simonneau, M. Humbert (2017)Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
The Lancet. Respiratory medicine, 5 2
H. Koiwa, I. Tsujino, D. Ikeda, H. Ohira, M. Tanino, M. Nishimura (2011)An autopsy case of pulmonary veno-occlusive disease refractory to imatinib
European Respiratory Journal, 37
S Adachi (2014)603
Intern Med, 53
D Nayyar (2014)342
Pulm Circ., 4
HA Ghofrani (2005)1412
N Engl J Med, 353
D Montani (2017)125
Lancet Respir Med, 5
M. Overbeek, G. Amerongen, A. Boonstra, E. Smit, A. Vonk-Noordegraaf (2008)Possible role of imatinib in clinical pulmonary veno-occlusive disease
European Respiratory Journal, 32
M. Hoeper, R. Barst, R. Bourge, J. Feldman, A. Frost, N. Galiè, M. Gómez-Sánchez, F. Grimminger, E. Grünig, P. Hassoun, N. Morrell, A. Peacock, T. Satoh, G. Simonneau, V. Tapson, F. Torres, D. Lawrence, D. Quinn, H. Ghofrani (2013)Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
M. Kataoka, Ryoji Yanagisawa, K. Fukuda, H. Yoshino, T. Satoh (2012)Sorafenib Is Effective in the Treatment of Pulmonary Veno-Occlusive Disease
M Humbert (2023)2200879
Eur Respir J, 61
H Koiwa (2011)968
Eur Respir J, 37
H. Wada, T. Nakajima, Hidemi Suzuki, Rie Anazawa, T. Narita, J. Terada, S. Yoshida, K. Tatsumi, Y. Nakatani, I. Yoshino (2019)Pulmonary capillary hemangiomatosis diagnosed by pathology of explanted lungs: a unique etiology serves as a key of clinical diagnosis
General Thoracic and Cardiovascular Surgery, 67
H. Ghofrani, W. Seeger, F. Grimminger (2005)Imatinib for the treatment of pulmonary arterial hypertension.
The New England journal of medicine, 353 13
A. Ogawa, K. Miyaji, H. Matsubara (2017)Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Respiratory medicine, 131
K Fukuda (2019)842
Circ J, 83
N Galiè, M Humbert, JL Vachiery, S Gibbs, I Lang, A Torbicki (2015)2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Eur Respir J, 46
MJ Overbeek (2008)232
Eur Respir J, 32
Dhruv Nayyar, K. Muthiah, G. Kumarasinghe, R. Hettiarachchi, D. Celermajer, E. Kotlyar, A. Keogh (2014)Imatinib for the Treatment of Pulmonary Arterial Hypertension and Pulmonary Capillary Hemangiomatosis
Pulmonary Circulation, 4
H Sato (2019)69
Tohoku J Exp Med, 247
M Kataoka (2012)172
K. Fukuda, H. Date, Shozaburo Doi, Y. Fukumoto, N. Fukushima, M. Hatano, Hiroshi Ito, M. Kuwana, H. Matsubara, S. Momomura, M. Nishimura, H. Ogino, T. Satoh, H. Shimokawa, K. Yamauchi-Takihara, K. Tatsumi, H. Ishibashi-Ueda, N. Yamada, S. Yoshida, K. Abe, A. Ogawa, T. Ogo, T. Kasai, M. Kataoka, Takashi Kawakami, S. Kogaki, Mashio Nakamura, T. Nakayama, M. Nishizaki, K. Sugimura, N. Tanabe, I. Tsujino, A. Yao, T. Akasaka, M. Ando, Takeshi Kimura, T. Kuriyama, N. Nakanishi, T. Nakanishi, H. Tsutsui (2019)Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017).
Circulation journal : official journal of the Japanese Circulation Society, 83 4
Rie Anazawa, J. Terada, S. Sakao, A. Shigeta, N. Tanabe, K. Tatsumi (2019)Features of radiological and physiological findings in pulmonary capillary hemangiomatosis: an updated pooled analysis of confirmed diagnostic cases
Pulmonary Circulation, 9
BW Holcomb Jr (2000)1671
R Anazawa (2019)1
Pulm Circ., 9
M. Humbert, G. Kovacs, M. Hoeper, R. Badagliacca, R. Berger, M. Brida, J. Carlsen, A. Coats, P. Escribano-Subías, P. Ferrari, D. Ferreira, H. Ghofrani, G. Giannakoulas, D. Kiely, E. Mayer, G. Meszaros, Blin Nagavci, K. Olsson, J. Pepke-Zaba, J. Quint, G. Rådegran, G. Simonneau, O. Sitbon, T. Tonia, M. Toshner, J. Vachiéry, A. Noordegraaf, M. Delcroix, S. Rosenkranz (2022)2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
European Respiratory Journal, 61
S. Adachi, A. Hirashiki, T. Kondo, M. Nakaguro, A. Ogawa, K. Miyaji, H. Matsubara, T. Yokoi, T. Murohara (2014)Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis.
Internal medicine, 53 6
D Montani (2016)1518
Eur Respir J, 47
H Wada (2019)332
Gen Thorac Cardiovasc Surg, 67
A Ogawa (2017)215
Respir Med, 131
BackgroundPulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare types of pulmonary arterial hypertension with dismal prognoses; there is no established medical treatment for these conditions. Possible efficacy of imatinib against these conditions has been reported in 15 cases; however, how and in whom imatinib is effective remain unknown.MethodsWe retrospectively evaluated clinical data from consecutive patients with PVOD/PCH treated with imatinib at our institution. The diagnosis of PVOD/PCH was established using the following criteria: pre-capillary pulmonary hypertension; diffusion capacity of the lung for carbon monoxide < 60%; and two or more high-resolution computed tomography findings of interlobular septal thickening, centrilobular opacities, and mediastinal lymphadenopathy. The dose of pulmonary vasodilators remained unchanged during the assessment of imatinib.ResultsThe medical records of five patients with PVOD/PCH were reviewed. The patients were aged 67 ± 13 years, their diffusion capacity of the lung for carbon monoxide was 29 ± 8%, and their mean pulmonary artery pressure was 40 ± 7 mmHg. Imatinib was administered at 50–100 mg/day; consequently, the World Health Organization functional class improved in one patient. In addition, imatinib improved the arterial oxygen partial pressure in this and another patient (these two also experienced a decreased mean pulmonary artery pressure and pulmonary vascular resistance after imatinib usage).ConclusionsThis study indicated that imatinib improves the clinical condition, including pulmonary hemodynamics, of some patients with PVOD/PCH. In addition, patients with a certain high-resolution computed tomography pattern or PCH-dominant vasculopathy may respond favorably to imatinib.
American Journal of Cardiovascular Drugs – Springer Journals
Published: May 1, 2023
Access the full text.
Sign up today, get DeepDyve free for 14 days.